Report on the First International Workshop on interim-PET scan in lymphoma
Top Cited Papers
- 1 January 2009
- journal article
- review
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 50 (8), 1257-1260
- https://doi.org/10.1080/10428190903040048
Abstract
An international workshop, under the auspices of Group d'Etude des Lymphomes de l'Adulte (GELA) took place in Deauville, France, in April 3–4, 2009. The European experts with a published or personal experience on interim-PET in lymphoma were invited to the meeting. The aim of the workshop was twofold: (1) to reach a consensus on simple, reproducible criteria for interim-PET interpretation in Hodgkin lymphoma and diffuse large B-cell lymphoma (DLBCL), and (2) to launch two or more international validation studies, in an attempt to validate these rules. We concisely report here the minutes of the meeting and the conclusions/statements that have been reached.Keywords
This publication has 6 references indexed in Scilit:
- Fluorine-18-Fluorodeoxyglucose Positron Emission Tomography for Interim Response Assessment of Advanced-Stage Hodgkin's Lymphoma and Diffuse Large B-Cell Lymphoma: A Systematic ReviewJournal of Clinical Oncology, 2009
- Prognostic Value of Interim 18F-FDG PET in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment at 4 Cycles of ChemotherapyJournal of Nuclear Medicine, 2009
- Early prediction of response to therapy: the clinical implications in Hodgkin’s and non-Hodgkin’s lymphomaEuropean Journal of Nuclear Medicine and Molecular Imaging, 2008
- Early Interim 2-[18F]Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography Is Prognostically Superior to International Prognostic Score in Advanced-Stage Hodgkin's Lymphoma: A Report From a Joint Italian-Danish StudyJournal of Clinical Oncology, 2007
- Use of Positron Emission Tomography for Response Assessment of Lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in LymphomaJournal of Clinical Oncology, 2007
- Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphomaAnnals of Oncology, 2005